Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Exosome Diagnostics, a Bio-Techne brand logo — ExoDx Prostate is the only exosome-based, non-DRE, simple ur...

Exosome Diagnostics, a Bio-Techne brand

ExoDx Prostate is the only exosome-based, non-DRE, simple urine test to assess risk for HGPCa and guide biopsy decision.

Founded 2008 United States Waltham, United States 103 employees Series C Total: $112.08M Biotechnology, Health Care

General Information

Company Name Exosome Diagnostics, a Bio-Techne brand
Founded Year 2008
Location United States Waltham, United States
Founders / Decision Makers
Team member
Employees 103
Industries Biotechnology, Health Care
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Exosome Diagnostics, a Bio-Techne brand. To contact Exosome Diagnostics, a Bio-Techne brand, visit exosomedx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Exosome Diagnostics, a Bio-Techne brand compare?

A PDF of Exosome Diagnostics, a Bio-Techne brand and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Exosome Diagnostics, a Bio-Techne brand soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Exosome Diagnostics, a Bio-Techne brand

Exosome Diagnostics, Inc., founded in 2008 and headquartered in the United States, is making significant strides in the biotechnology and healthcare industries. The company's slogan, "ExoDx Prostate is the only exosome-based, non-DRE, simple urine test to assess risk for HGPCa and guide biopsy decision," encapsulates its pioneering approach. Exosome Diagnostics is focused on commercializing minimally invasive molecular diagnostics in blood and urine, offering a breakthrough in guiding physicians to select optimal therapies for cancer and other diseases. The company's innovation lies in its utilization of exosomes, which are lipid bilayer-covered microvesicles shed by solid tumors into body fluids. These exosomes contain nucleic acid profiles of cancers and other diseases, serving as valuable indicators for diagnosis and treatment selection. Notably, Exosome Diagnostics has achieved compelling results in extracting exosomes from patients' blood and urine, detecting key genes and gene mutations associated with various cancers with high sensitivity and specificity. In their last funding round in July 2017, Exosome Diagnostics secured a substantial $30.00M Series C investment. This capital injection was provided by a distinguished group of investors including Forbion, Arcus Ventures, NGN Capital, Tiger Infrastructure Partners, b2venture (formerly btov Partners), CD-Venture, and Blue Ridge Capital. This financial backing is a testament to the confidence placed in Exosome Diagnostics' groundbreaking approach and its potential to revolutionize diagnostics and treatment selection in the healthcare industry.

Business keywords: exosome-based diagnostics, liquid biopsy, prostate cancer, biopsy decision, molecular diagnostics, minimally invasive, nucleic acid profiles, cancer detection, urine test, blood test, cancer therapies, non-invasive testing, cancer biomarkers, precision medicine

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $30.00M 7
Forbion Arcus Ventures b2venture
Forbion, Arcus Ventures +5
24 Jul 2017
Series B $16.00M 7
Forbion Arcus Ventures Tiger Management Corp
Forbion, Arcus Ventures +5
07 Jan 2016
Series B $17.60M 5
Forbion Arcus Ventures Tiger Management Corp
Forbion, Arcus Ventures +3
02 Sep 2015
Venture Round $1.48M -
06 Jul 2015
Series B $27.00M 7
Forbion Arcus Ventures b2venture
Forbion, Arcus Ventures +5
11 Mar 2014
Series A $20.00M 2
Forbion NGN Capital
Forbion, NGN Capital
11 May 2010

Exosome Diagnostics, a Bio-Techne brand Alternatives & Competitors

View All Alternatives
Exosome Diagnostics, a Bio-Techne brand vs
Nucleix Ltd.
Nucleix Ltd. Israel

Developing cancer diagnostic panels based on epigenetic bio markers

72 employees
Biotechnology, Health Care
Compare Exosome Diagnostics, a Bio-Techne brand vs Nucleix Ltd.
Exosome Diagnostics, a Bio-Techne brand vs
RhoDx, Inc.
RhoDx, Inc. United States

Reducing Cancer Morbidity and Mortality through Early Detection and Monitoring.

3 employees
Biotechnology, Health Care
Compare Exosome Diagnostics, a Bio-Techne brand vs RhoDx, Inc.
Exosome Diagnostics, a Bio-Techne brand vs
VisionGate, Inc.
VisionGate, Inc. United States

Leading the Battle Against Lung Cancer through our Early Detection Technology

Venture round
24 employees
Biotechnology, Health Care
Also compare with: Exosome Diagnostics, a Bio-Techne brand vs Coyote Bioscience Coyote Bioscience View all alternatives

FAQ About Exosome Diagnostics, a Bio-Techne brand

ExoDx Prostate is the only exosome-based, non-DRE, simple urine test to assess risk for HGPCa and guide biopsy decision.
Exosome Diagnostics, a Bio-Techne brand was founded in 2008.
Exosome Diagnostics, a Bio-Techne brand is headquartered in Waltham, United States.
Exosome Diagnostics, a Bio-Techne brand operates in Biotechnology and Health Care. Its work centres on exosome-based diagnostics, liquid biopsy, prostate cancer and biopsy decision.
Exosome Diagnostics, a Bio-Techne brand has approximately 103 employees.
Exosome Diagnostics, a Bio-Techne brand has completed 6 funding rounds, raising a total of $112.08M. The latest funding stage is Series C.
Top alternatives and competitors to Exosome Diagnostics, a Bio-Techne brand include Nucleix Ltd., RhoDx, Inc., VisionGate, Inc., Diatech Pharmacogenetics, Coyote Bioscience. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Exosome Diagnostics, a Bio-Techne brand and Nucleix Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Exosome Diagnostics, a Bio-Techne brand, https://bouncewatch.com/company/exosome-diagnostics, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes